The Craneware (LON:CRW) investment case has now suffered its biggest setback in years. A trading update issued on 3 July warned that full-year revenue and earnings will come in below market expectations after delays in recognising revenue from eligible activity within the US 340B drug pricing programme and the deferral of several significant enterprise software … Continue reading Craneware’s profit warning: buying opportunity or the end of its premium rating?